Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Kyverna is seeking a Senior Manager/Associate Director of Site Activation responsible for developing and executing strategic account plans across health systems, IDNs, and treatment centers to drive activation, adoption, and sustained utilization of the company's cell therapy portfolio. This individual serves as the primary commercial and operational partner to key accounts, coordinating cross-functional resources to optimize customer experience, remove barriers to patient access, and expand treatment capacity.
Title Sr. Manager / Assoc Director Site Activation
Reports To VP Sales and Site Operations
Location Remote
Travel 50–70%The national salary range for this position is from $150K to $200K USD annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on education, experience, skills, internal equity, and market data. This position is also eligible for bonus, benefits, and participation in the Company's stock plan.
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
